Suchergebnisse - "Dispenzieri, Angela"

PubPharm (38)

1

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

enthalten in: Blood cancer journal | 2024

von Goel, U. | Charalampous, C. | Kapoor, P. | +18

2

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

enthalten in: Haematologica | 2023

von Richardson, P. | Durie, B. | Rosiñol, L. | +15

3

Thrombosis in multiple myeloma : Risk estimation by induction regimen and association with overall survival

enthalten in: American journal of hematology | 2023

von Charalampous, C. | Goel, U. | Kapoor, P. | +18

4

A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis

enthalten in: Leukemia | 2022

von Dispenzieri, A. | Kastritis, E. | Wechalekar, A. | +12

5

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)

enthalten in: Blood cancer journal | 2021

von Ho, M. | Zanwar, S. | Kapoor, P. | +16

6

Expert review on soft-tissue plasmacytomas in multiple myeloma : definition, disease assessment and treatment considerations

enthalten in: British journal of haematology | 2021

von Rosiñol, L. | Beksac, M. | Zamagni, E. | +35

7

Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy

enthalten in: American journal of hematology | 2021

von Wudhikarn, K. | Padrnos, L. | Lasho, T. | +13

8

Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma

enthalten in: American journal of hematology | 2021

von Cook, J. | Johnson, I. | Higgins, A. | +19

9

Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM : FIRST trial subanalysis of Canadian/US patients

enthalten in: Cancer medicine | 2020

von Belch, A. | Bahlis, N. | White, D. | +11

10

Longer term follow-up of the randomized phase III trial SWOG S0777 : bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

enthalten in: Blood cancer journal | 2020

von Durie, B. | Hoering, A. | Sexton, R. | +10